CClinicalTrials.gg
Status unknownNCT03867266FLAIUpdated Mar 7, 2019

Typical Atrial Flutter, Ablation Index and Point by Point Ablation

An observational study in Typical Atrial Flutter, sponsored by Ospedale San Francesco. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-03-07.

Sponsored by Ospedale San Francesco · Observational

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The Ablation of the typical atrial flutter can be considered substantially anatomical, the investigators want to test a protocol that foresees the use a lesion index (AI) and that respects the Inter-Lesion Distance (ILD) ≤ 6 mm on the cavo-tricuspid isthmus (CTI) The investigators want to prove how the introduction of a lesion index combined with the continuity of lesion can allow a "first pass block" of the CTI decreasing total Radio-Frequency (RF) times

Read the detailed description

The Ablation of the typical atrial flutter can be considered substantially anatomical, the aim of the study is to test a protocol that foresees the use a lesion index and that respects the Inter-Lesion Distance ≤ 6 mm on the cavo-tricuspid isthmus to prove how the introduction of a lesion index combined with the continuity of lesion can allow a "first pass block" of the CTI decreasing total Radio-Frequency times With the aim of reducing the use of the fluoroscopy and ionizing radiations, an anatomical map of the right atrium will be reconstructed with a mapping catheter in all patients, and a 10-pole catheter will be placed in the coronary sinus.Then, the anatomy of the isthmus will be precisely defined with a catheter equipped with a force sensor ,identifying the tricuspid valve as the initial point of ablation and the inferior vena cava- right atrium junction as the end point of the line.Once the reconstruction has been completed, the ablation phase will start. Considering the values already validated for the left atrium, the protocol foresees the point-by-point ablation with the use of AI ≥ 500 and ILD≤ 6 mm.

The Visitag setting will be the following:

  • Respiration Adjustment;
  • Catheter Position Stability Min. Time = 3 sec, Max. Range = 5 mm;
  • Force Over Time Time = 30% Min. Force = 4 gr. The power can be set between 35 and 40 watts. At the end of the isthmus ablation, line block will be evaluated by proximal CS pacing, acquiring at least 3 distinct points from the ablator catheter around the tricuspid annulus ,typically ostium of coronary sinus (CS), lateral tricuspid annulus and a point more proximal to the line of ablation.

Once this phase has been completed, 20 minutes of waiting time has to be considered. After this waiting time the block of the isthmus will be validated again with the same protocol described above.

Primary Endpoint -Anatomical first Pass block of the CTI.

Secondary Endpoint

-Reduction of procedural, RF and fluoroscopy times.

02

Conditions studied

  • Typical Atrial Flutter

Browse trials for

Keywords

  • Ablation index
  • Interlesion distance
03

In context

Atrial Flutter

213 studies on the registry are indexed under Atrial Flutter; 50 are open to participants now.

This study's planned enrollment of 400 is above the median of 232 across 59 observational studies indexed under Atrial Flutter.

Browse Atrial Flutter studies →

Lead sponsor

This is the only study on the registry with Ospedale San Francesco as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Caucasian population regardless gender

Inclusion criteria

  • paroxysmal, persistent and /or long standing atrial flutter even in the presence of structural heart disease
  • Informed consent form
  • Age equal or above 18 years
  • Skilled and willing to comply with all tests and follow up requirements
  • Patients that ,in the context of ablation for fibrillation atrial, should also undergo to typical flutter ablation: in this case the data collected will be those related to typical flutter ablation.

Exclusion criteria

Exclusion Criteria:

  • Previous ablation for atrial flutter
  • Atrial flutter secondary to electrolyte imbalance, thyroid disease or to a reversible or non-cardiac cause
  • severe anemia,
  • sepsis in progress
  • Bypass procedure with coronary arterial artery in the last three months
  • Pending cardiac transplantation or other cardiac surgery
  • Pregnant or breastfeeding women
  • Acute disease or active systemic infection or sepsis
  • Documented left atrial thrombus
  • Unstable angina
  • Uncontrolled heart failure
  • Life expectancy of less than 12 months
  • Registration in any other study evaluating another device or medication
  • Presence of intramural thrombi, tumor or other anomalies that preclude the introduction of the catheter into the vein system
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Interventions

  • ProcedureAblation with radiofrequency

    Ablation point by point on the cavo tricuspid isthmus guided by an index lesion

06

What researchers measure

Primary outcomes

  1. First pass block of the cavo tricuspid isthmus

    Validation of the bidirectional block by pacing on the coronary sinus after completing the first line of the ablation

    Time frame: 9 months

Secondary outcomes

  1. radiofrequency time of application

    reduction in radio frequency time in comparison with current literature

    Time frame: 9 months

  2. Near zero x ray

    reduction of x-ray time

    Time frame: 9 months

  3. Procedural time

    reduction in procedural time in comparison with current literature

    Time frame: 9 months

07

Study locations

1 of 1 sites recruiting
  • Ospedale San Francesco
    Nuoro, 08100, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03867266
Lead sponsor
Ospedale San Francesco
Responsible party
Graziana Viola (Medical Doctor, Ospedale San Francesco) — Principal investigator
First posted
Mar 7, 2019
Start date
Feb 20, 2019
Primary completion
Jun 1, 2019 (estimated)
Completion
Jul 1, 2019 (estimated)
Last update
Mar 7, 2019

Study contacts

Graziana Viola, Medicine
Contact
grazianaviola@gmail.com
+393401403816

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion